DEFA14A: Bionomics Corrects Record Date Details for Neuphoria Share Distribution in Re-domiciliation Scheme

Bionomics has filed a supplement to its proxy statement to correct an error regarding the record date for ADS holders to receive Neuphoria shares in the proposed re-domiciliation scheme.

Summary

• Bionomics Limited filed a supplement to its proxy statement to correct an error regarding the record date for American Depositary Share (ADS) holders to receive Neuphoria shares.
• The original proxy statement incorrectly described the record date for ADS holders to receive Neuphoria shares upon implementation of the Scheme of Arrangement.
• The voting record date for ADS holders remains October 25, 2024, but the record date for receiving Neuphoria shares will be determined by the Depositary.
• The Depositary will use reasonable efforts to set the record date for ADS holders as close as practicable to the record date for holders of ordinary shares under the Scheme.
• Under the scheme, Bionomics shareholders will receive one Neuphoria share for every 2,160 Bionomics shares owned.
• ADS holders will receive one Neuphoria share for every 12 Bionomics ADSs held as of the record date established by the Depositary.
• Upon completion of the scheme, Bionomics will become a wholly-owned subsidiary of Neuphoria, and Neuphoria will become the successor issuer of Bionomics.
• Neuphoria shares are expected to trade on Nasdaq under the ticker symbol NEUP.

Sentiment

Score: 7

Explanation: The document is primarily a correction of an error, which is a neutral event. The re-domiciliation plan is still progressing as expected, which is positive.

Positives

• The company is proactively correcting an error in its proxy statement to ensure accurate information is provided to shareholders.
• The re-domiciliation to Delaware is still progressing as planned.

Negatives

• An error was made in the original proxy statement regarding the record date for ADS holders, which required a supplement to be filed.

Risks

• The Depositary's determination of the record date for ADS holders could introduce some uncertainty for those investors.
• The re-domiciliation process is complex and subject to shareholder and court approval.

Future Outlook

The company anticipates that Neuphoria shares will trade on Nasdaq under the ticker symbol NEUP upon completion of the scheme.

Industry Context

Re-domiciliation is a strategic move for companies seeking to optimize their corporate structure and access different capital markets, and this move is in line with other companies seeking a US listing.

Comparison to Industry Standards

• Re-domiciliation to Delaware is a common practice for companies seeking to list on US exchanges, similar to other companies that have made the move to access US capital markets.
• The share exchange ratio is specific to Bionomics and its valuation, and is not directly comparable to other companies.

Stakeholder Impact

• Shareholders will receive Neuphoria shares in exchange for their Bionomics shares or ADSs.
• The re-domiciliation is intended to benefit shareholders by providing access to US capital markets.

Next Steps

• Shareholders will vote on the Scheme of Arrangement.
• The court will need to approve the Scheme.
• The Depositary will determine the record date for ADS holders to receive Neuphoria shares.
• Neuphoria shares will begin trading on Nasdaq under the ticker symbol NEUP upon completion of the scheme.

Key Dates

Keywords

Bionomics, Neuphoria, Re-domiciliation, Scheme of Arrangement, Proxy Statement, ADS, Record Date, Nasdaq, NEUP